← Back to Search

Dexamethasone Eye Drops for Post-Cataract Surgery Care (OPTIMIZE-2 Trial)

Phase 3
Recruiting
Research Sponsored by Oculis
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Will undergo unilateral cataract extraction via phacoemulsification and PCIOL implantation in the study eye
Be older than 18 years old
Must not have
Have only one functional eye (monocular)
Have any intraocular inflammation (e.g., white blood cells or flare) present in either eye at the Visit 1 (Day -1 to Day -28 [prior to surgery]) slit-lamp examination
Timeline
Screening 3 weeks
Treatment Varies
Follow Up visit 6 (day 15)
Awards & highlights

Summary

This trial tests if a new drug is safe & effective for treating eye inflammation & pain after surgery.

Who is the study for?
This trial is for adults of any sex or race who are undergoing cataract surgery and will have an intraocular lens implanted. Participants must be able to follow the study plan and visits, and have a certain level of inflammation after surgery. People with allergies to dexamethasone or corticosteroids, those with one functional eye, or pre-existing eye inflammation can't join.
What is being tested?
The study tests OCS-01 Eye Drops against a placebo (vehicle of OCS-01) to see if they're effective in reducing pain and inflammation after cataract surgery. Patients receive either the actual medication or placebo without knowing which one.
What are the potential side effects?
Possible side effects may include reactions at the application site like burning or stinging sensation, increased risk of infection due to immune suppression by steroids, elevated eye pressure, and potential worsening of existing infections.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am scheduled for a specific cataract surgery in one eye.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I can see with only one of my eyes.
Select...
I have signs of eye inflammation detected in a recent exam.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~visit 6 (day 15)
This trial's timeline: 3 weeks for screening, Varies for treatment, and visit 6 (day 15) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
To evaluate the efficacy of OCS-01 to control inflammation in subjects after cataract surgery
To evaluate the efficacy of OCS-01 to control pain in subjects after cataract surgery

Side effects data

From 2015 Phase 2 trial • 36 Patients • NCT02011113
72%
NEUTROPENIA
47%
ANAEMIA
44%
THROMBOCYTOPENIA
25%
NASOPHARYNGITIS
25%
PYREXIA
25%
CONSTIPATION
22%
LYMPHOPENIA
19%
DIARRHOEA
19%
OEDEMA PERIPHERAL
19%
NAUSEA
19%
RASH
17%
LEUKOPENIA
17%
INSOMNIA
17%
MALAISE
14%
PNEUMONIA
14%
DYSGEUSIA
11%
FATIGUE
11%
EPISTAXIS
11%
DECREASED APPETITE
11%
HYPERURICAEMIA
11%
HYPOALBUMINAEMIA
11%
UPPER RESPIRATORY TRACT INFECTION
11%
HYPOKALAEMIA
8%
RASH MACULO-PAPULAR
8%
Pharyngitis
8%
HYPERGLYCAEMIA
8%
HYPOPHOSPHATAEMIA
8%
HYPOXIA
8%
ANXIETY
8%
MYALGIA
8%
HEPATIC FUNCTION ABNORMAL
8%
HERPES ZOSTER
6%
CANCER PAIN
6%
DECUBITUS ULCER
6%
PERIPHERAL SENSORY NEUROPATHY
6%
INCREASED APPETITE
6%
CYSTITIS
6%
DIABETES MELLITUS
6%
GASTROENTERITIS
6%
RESTLESSNESS
6%
HEADACHE
6%
NEUROPATHY PERIPHERAL
6%
WEIGHT INCREASED
6%
HYPOTENSION
6%
HYPOGAMMAGLOBULINAEMIA
6%
ABDOMINAL PAIN UPPER
6%
HAEMORRHOIDS
6%
ASTHMA
6%
VOMITING
6%
BRONCHITIS
6%
HYPERCALCAEMIA
6%
HYPOCALCAEMIA
6%
HYPONATRAEMIA
6%
HYPERSOMNIA
6%
DYSPHONIA
6%
PLEURAL EFFUSION
6%
HICCUPS
6%
ALANINE AMINOTRANSFERASE INCREASED
6%
ASPARTATE AMINOTRANSFERASE INCREASED
6%
BLOOD ALKALINE PHOSPHATASE INCREASED
6%
MUSCLE SPASMS
6%
WEIGHT DECREASED
6%
TREMOR
6%
HYPOTHYROIDISM
6%
SOMNOLENCE
6%
PROCTALGIA
6%
DYSPNOEA
3%
PNEUMONIA PNEUMOCOCCAL
3%
MULTI-ORGAN FAILURE
3%
PNEUMOCYSTIS JIROVECII PNEUMONIA
3%
SEPSIS
3%
INTERSTITIAL LUNG DISEASE
3%
C-REACTIVE PROTEIN INCREASED
3%
CARDIAC FAILURE
3%
CHRONIC OBSTRUCTIVE PULMONARY DISEASE
3%
URINARY RETENTION
3%
MENINGITIS
3%
SPINAL COMPRESSION FRACTURE
3%
BLOOD FIBRINOGEN DECREASED
3%
BACK PAIN
3%
SHOCK HAEMORRHAGIC
100%
80%
60%
40%
20%
0%
Study treatment Arm
Pomalidomide Plus Dexamethasone

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: OCS-01Experimental Treatment1 Intervention
dexamethasone ophthalmic suspension,1.5% \[15 mg/mL\]
Group II: Vehicle ophthalmic suspensionPlacebo Group1 Intervention
Vehicle of OCS-01

Find a Location

Who is running the clinical trial?

OculisLead Sponsor
8 Previous Clinical Trials
1,570 Total Patients Enrolled
2 Trials studying Cataract
393 Patients Enrolled for Cataract
ORA, Inc.Industry Sponsor
69 Previous Clinical Trials
8,799 Total Patients Enrolled
~91 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top